Literature DB >> 22019178

Endovascular revascularization of below-the-knee arteries: prospective short-term angiographic and clinical follow-up.

Frederic Baumann1, Torsten Willenberg, Dai-Do Do, Hak-Hong Keo, Iris Baumgartner, Nicolas Diehm.   

Abstract

PURPOSE: To evaluate arterial lesion characteristics and their impact on angiographic and clinical outcomes after endovascular below-the-knee (BTK) revascularization.
MATERIALS AND METHODS: Between April 2008 and June 2009, 33 patients (mean age 74.9 years) with 34 limbs and 50 arterial segments (mean lesion length 59.3 mm) undergoing endovascular BTK revascularization agreed to undergo prospective clinical and intraarterial angiographic 6-month follow-up evaluation. Clinical indication for BTK revascularization was critical limb ischemia (CLI) in 18 patients and delayed wound healing without hemodynamic evidence of CLI and intermittent claudication (IC) in 15 patients.
RESULTS: Binary restenosis was observed in 40% of treated segments at 6 months. Primary sustained clinical improvement was 82.4% and 55.9% at 3 months and 6 months. Lesion length was independently associated with binary restenosis (hazard ratio [HR] 1.013, 95% confidence interval [CI] 1.000-1.016, P = .05) and lower rates of primary sustained clinical improvement (HR 1.024, 95% CI 1.006-1.042, P = .008).
CONCLUSIONS: Endovascular BTK revascularization yields clinical and angiographic benefits both for patients with IC and for patients with CLI. Although arterial lesion length adversely affects angiographic and clinical outcomes after endovascular revascularization, limb salvage rates were substantially higher compared with the comparatively low patency rates after BTK angioplasty.
Copyright © 2011 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22019178     DOI: 10.1016/j.jvir.2011.08.028

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  4 in total

1.  [Efficacy of drug-coated balloon and common balloon for treatment of superficial femoral artery and popliteal artery arteriosclerosis obliterans: prospective randomized controlled triac].

Authors:  Jing-Yuan Lu; Jian-Ping Gu; Wen-Jian Xu; Wen-Sheng Lou; Tao Wang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-03-20

Review 2.  The Impact of Antithrombotic Regimens on Clinical Outcomes After Endovascular Intervention and Bypass Surgery for Infrapopliteal Artery Disease.

Authors:  Amol Gupta; Michael S Lee; Kush Gupta; Vinod Kumar; Sarath Reddy
Journal:  Cardiol Res       Date:  2019-10-04

3.  IN.PACT Amphirion paclitaxel eluting balloon versus standard percutaneous transluminal angioplasty for infrapopliteal revascularization of critical limb ischemia: rationale and protocol for an ongoing randomized controlled trial.

Authors:  Thomas Zeller; Iris Baumgartner; Dierk Scheinert; Marianne Brodmann; Marc Bosiers; Antonio Micari; Patrick Peeters; Frank Vermassen; Mario Landini
Journal:  Trials       Date:  2014-02-19       Impact factor: 2.279

4.  Value of S100A12 in predicting in-stent restenosis in patients with coronary drug-eluting stent implantation.

Authors:  Hengyi Liang; Yuqi Cui; Haoran Bu; Hang Liu; Pengcheng Yan; Lianqun Cui; Liming Chen
Journal:  Exp Ther Med       Date:  2020-05-06       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.